S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
What Should Investors Make of These 3 Dividend Cuts?
⚡ 2,467% Return on Israeli Laser Company? (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Trading Channel Breakout in Lululemon Brought by Earnings
⚡ 2,467% Return on Israeli Laser Company? (Ad)
Constellation Brands Taps into Growth: Analysts Bullish on Stock
Salesforce: Time to Snap it Up as the Market Buys the Dip?
⚡ 2,467% Return on Israeli Laser Company? (Ad)
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
MarketBeat Week in Review – 5/29 - 6/2
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
What Should Investors Make of These 3 Dividend Cuts?
⚡ 2,467% Return on Israeli Laser Company? (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Trading Channel Breakout in Lululemon Brought by Earnings
⚡ 2,467% Return on Israeli Laser Company? (Ad)
Constellation Brands Taps into Growth: Analysts Bullish on Stock
Salesforce: Time to Snap it Up as the Market Buys the Dip?
⚡ 2,467% Return on Israeli Laser Company? (Ad)
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
MarketBeat Week in Review – 5/29 - 6/2
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
What Should Investors Make of These 3 Dividend Cuts?
⚡ 2,467% Return on Israeli Laser Company? (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Trading Channel Breakout in Lululemon Brought by Earnings
⚡ 2,467% Return on Israeli Laser Company? (Ad)
Constellation Brands Taps into Growth: Analysts Bullish on Stock
Salesforce: Time to Snap it Up as the Market Buys the Dip?
⚡ 2,467% Return on Israeli Laser Company? (Ad)
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
MarketBeat Week in Review – 5/29 - 6/2
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
What Should Investors Make of These 3 Dividend Cuts?
⚡ 2,467% Return on Israeli Laser Company? (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Trading Channel Breakout in Lululemon Brought by Earnings
⚡ 2,467% Return on Israeli Laser Company? (Ad)
Constellation Brands Taps into Growth: Analysts Bullish on Stock
Salesforce: Time to Snap it Up as the Market Buys the Dip?
⚡ 2,467% Return on Israeli Laser Company? (Ad)
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
MarketBeat Week in Review – 5/29 - 6/2
TSE:MDNA

Medicenna Therapeutics (MDNA) Stock Forecast, Price & News

C$0.79
0.00 (0.00%)
(As of 06/2/2023 ET)
Compare
Today's Range
C$0.79
C$0.82
50-Day Range
C$0.72
C$1.11
52-Week Range
C$0.54
C$2.38
Volume
23,512 shs
Average Volume
22,562 shs
Market Capitalization
C$55.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
C$5.33

MDNA stock logo

About Medicenna Therapeutics (TSE:MDNA) Stock

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.

Receive MDNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medicenna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MDNA Stock News Headlines

“One-Stock Millionaire” IGNORES 99.9% of the Market
During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.
Medicenna Therapeutics Earnings Preview
Earnings Preview For Medicenna Therapeutics
“One-Stock Millionaire” IGNORES 99.9% of the Market
During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.
CIG, GRTX and MDNA among pre market gainers
See More Headlines

MDNA Price History

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
13
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
C$5.33
High Stock Price Forecast
C$9.00
Low Stock Price Forecast
C$2.00
Forecasted Upside/Downside
+575.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
C$-9,400,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
C$0.69 per share
Book Value
C$0.48 per share

Miscellaneous

Free Float
N/A
Market Cap
C$55.02 million
Optionable
Not Optionable
Beta
0.53

Key Executives

  • Dr. Fahar Merchant Ph.D. (Age 65)
    Founder, Chairman, Pres & CEO
    Comp: $462.15k
  • Ms. Rosemina Merchant B.Sc. (Age 65)
    M.E.Sc, Founder, Chief Devel. Officer & Director
    Comp: $370.62k
  • Ms. Elizabeth Williams C.A. (Age 44)
    CPA, CA, CPA, CFO & Corp. Sec.
    Comp: $311k
  • Dr. Martin Bexon M.D.
    MBBS, Acting Chief Medical Officer & Head of Clinical Devel.
  • Dr. Samuel R. Denmeade M.D.
    Scientific Advisor













MDNA Stock - Frequently Asked Questions

Should I buy or sell Medicenna Therapeutics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medicenna Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MDNA shares.
View MDNA analyst ratings
or view top-rated stocks.

What is Medicenna Therapeutics' stock price forecast for 2023?

5 brokerages have issued 1-year price targets for Medicenna Therapeutics' stock. Their MDNA share price forecasts range from C$2.00 to C$9.00. On average, they expect the company's share price to reach C$5.33 in the next year. This suggests a possible upside of 575.1% from the stock's current price.
View analysts price targets for MDNA
or view top-rated stocks among Wall Street analysts.

How have MDNA shares performed in 2023?

Medicenna Therapeutics' stock was trading at C$0.64 on January 1st, 2023. Since then, MDNA shares have increased by 23.4% and is now trading at C$0.79.
View the best growth stocks for 2023 here
.

What other stocks do shareholders of Medicenna Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medicenna Therapeutics investors own include OPKO Health (OPK), AbbVie (ABBV), Livongo Health (LVGO), Aptose Biosciences (APTO), Birchcliff Energy (BIR), CVS Health (CVS), Freehold Royalties (FRU), Fastly (FSLY) and Inovio Pharmaceuticals (INO).

What is Medicenna Therapeutics' stock symbol?

Medicenna Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "MDNA."

How do I buy shares of Medicenna Therapeutics?

Shares of MDNA stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Medicenna Therapeutics' stock price today?

One share of MDNA stock can currently be purchased for approximately C$0.79.

How much money does Medicenna Therapeutics make?

Medicenna Therapeutics (TSE:MDNA) has a market capitalization of C$55.02 million. The company earns C$-9,400,000.00 in net income (profit) each year or C($0.15) on an earnings per share basis.

How can I contact Medicenna Therapeutics?

Medicenna Therapeutics' mailing address is 2440 Kensington Rd NW, CALGARY, AB T2N 3S1, Canada. The official website for the company is www.medicenna.com. The company can be reached via phone at +1-403-6807898.

This page (TSE:MDNA) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -